New publication
2020. September 16.
A systematic review entitled "Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries" aimed to facilitate the development of future MCDA frameworks, by proposing a set of criteria focusing on the purchasing decisions of single-source innovative pharmaceuticals in upper middle-income countries. Syreon colleagues were able to establish a pool of 16 criteria that can serve as a basis for constructing MCDAs to inform reimbursement decision making of innovative pharmaceuticals.
Link: https://bit.ly/33BGPmW
